Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2025-12-25 @ 6:57 PM
Study NCT ID:
NCT05475704
Status:
COMPLETED
Last Update Posted:
2023-08-25
First Post:
2022-07-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
Sponsor:
P95
Organization:
Study Overview
Official Title:
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes, and when administered in different schedules.
Detailed Description:
This multi-country study seeks to collect RWE, from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes and when administered in different schedules.
The vaccines of interest are the following:
* 'Sinovac-CoronaVac' (Sinovac Biotech Ltd., Beijing, China),
* 'BIBP COVID-19 Vaccine' ('Covilo'; 'BIBP-CorV') (Sinopharm, Beijing Institute of Biological Products, China),
* 'Convidecia' ('AD5-nCOV') (CanSino Biologics, Tianjin, China).
The vaccines of interest are the following:
* 'Sinovac-CoronaVac' (Sinovac Biotech Ltd., Beijing, China),
* 'BIBP COVID-19 Vaccine' ('Covilo'; 'BIBP-CorV') (Sinopharm, Beijing Institute of Biological Products, China),
* 'Convidecia' ('AD5-nCOV') (CanSino Biologics, Tianjin, China).
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: